Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Type of publications
Guidelines (30)
NITAG documentation (1591)
Reports (55)
SAGE documentation (218)
Scientific publications (112)
Systematic reviews (SYSVAC) (2750)
Regions
Africa (267)
Americas (762)
Eastern Mediterranean (48)
Europe (704)
South-East Asia (78)
Western Pacific (196)
Diseases
Chikungunya (9)
Cholera (33)
COVID-19 (1481)
Cytomegalovirus (1)
Dengue (39)
Diphtheria (79)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (66)
Hepatitis A (63)
Hepatitis B (153)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (66)
HIV / AIDS (10)
Human papillomavirus (HPV) (472)
Influenza (573)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (27)
Measles (128)
Meningococcal disease (145)
Mpox (55)
Mumps (46)
Pertussis (104)
Pneumococcal disease (266)
Poliomyelitis (84)
Q fever (1)
Rabies (28)
Rotavirus (115)
RSV (Respiratory syncytial virus) (47)
Rubella (64)
Salmonella (2)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (59)
Tick-borne encephalitis (12)
Tuberculosis (73)
Typhoid (23)
Varicella (69)
Yellow fever (42)
Zika (1)
Show more
4756 results found
2020
∙
CAVEI
CAVEI ordinary meeting March 4th 2020
2020
∙
CAVEI
CAVEI provisional recommendation for the initial prioritization of groups to be vaccinated against SARS-CoV-2 in the context of limited supply
2020
∙
CAVEI
CAVEI recommendations to prioritize vaccination against SARS-COV-2 in health personnel during the campaign initiation phase and in the context of vaccine limited supply
2020
∙
Steve Anderson
CBER Plans for Monitoring COVID-19 Vaccine Safety and Effectiveness
2020
∙
Tom Shimabukuro, ACIP
CDC post-authorization/post-licensure safety monitoring of COVID-19 vaccines
2020
Charter of the Advisory Committee on Immunization Practices (ACIP)
2020
∙
Sara Oliver, ACIP
Clinical Considerations for Populations Included in Phase 1a
2020
∙
ACIP
Considerations for FDA Licensure vs. Emergency Use Authorization of COVID-19 Vaccines
2020
∙
Sara Oliver, ACIP
Considerations for Populations Included in Phase 1b and 1c
2020
COVID-19 vaccination: BioNTech/Pfizer
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register